Trade Microbot Medical Inc. - MBOT CFD

Trading Conditions

• Spread: 0.05
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 0.84
• Open: 0.85
• 1-Year Change: -42.57%
• Day's Range: 0.84 - 0.86

Microbot Medical Inc. Company profile

About Microbot Medical Inc

Microbot Medical Inc. is a pre-clinical medical device company. The Company is focused on the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Its technological platforms are comprised of ViRob, TipCAT and Liberty, including certain CardioSert assets. Using the ViRob platform, Microbot is developing the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH). Utilizing the Liberty and CardioSert platforms, it is developing disposable robot for various endovascular interventional procedures. ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. TipCAT is a disposable self-propelled locomotive device, designed to advance in tubular anatomies. Liberty is a disposable robotic system, designed to move guidewires and over-the-wire devices, such as microcatheters within the body’s vasculature.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Microbot Medical Inc revenues was not reported. Net loss increased 14% to $7.5M. Higher net loss reflects Research and development increase of 63% to $3.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.92 to -$1.05.

Equity composition

Common $.1 Par, 07/11, 250M auth., 13,784,019 issd,. Insiders control approx. 8.68%. IPO 3/92, 2.25M shares @ $11.00 by Robertson, Stephens & Co. PO 9/95, 2.3M shares @ $9.375. 10/93, *5/00, Name changed from Cytotherapeutics, Inc. PO: 11/08, 13.8M shares. 07/11, 1-for-10 reverse stock split. 05/16 1-for-12 reverse stock split.